What the trial was testing
The trial enrolled 81 patients with type 1 diabetes. The study was sponsored by University of Cambridge and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Kids using the automated system spent 9% more time in a healthy blood sugar range each day.
The New England journal of medicine · 2022 · NCT03784027
These findings — that kids' blood sugar stayed in the healthy zone more of each day with the automated pump — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 81 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 1 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If your young child has type 1 diabetes, this automated system is FDA-approved and could make managing blood sugar much easier. It works like an artificial pancreas — constantly monitoring glucose and adjusting insulin automatically. Ask your child's endocrinologist if this technology is right for your family.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 1 diabetes trials
The iLet Experience Study
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.